Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Wake Forest University Health Sciences
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02162225CT.gov Study of Beet Juice for Patients With Sickle Cell Anemia | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sickle Cell Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Beetroot Juice - Active (this asset) | Wake Forest University Health Sciences | P2 | CCC · 51 |
| Hydroxyurea | St. Jude Children's Research Hospital | P4 | BBB |
| Crizanlizumab | Novartis Pharmaceuticals | P4 | BB |
| Nivestim | St. Jude Children's Research Hospital | P4 | BB |
| Nepenthe | Oman Medical Speciality Board | P4 | BB |
| ARG | Tanta University | P3 | BB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2/3 | BB |
| Magnesium Metallicum | Medical College of Wisconsin | P3 | BB |
| Glutamine | Ain Shams University | P4 | BB |
+42 more in the Sickle Cell Disease cohort
Other indications for Beetroot Juice - Active
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Stroke Disorder | — | P2 | CCC · 48 |
| Ischemic Stroke | — | P2 | CCC · 48 |
| Muscular Dystrophy | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Beetroot Juice - Active in Sickle Cell Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/beetroot-juice-active-sickle-cell-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →